Adenosine A_2A receptor agonists inhibit lipopolysaccharide-induced production of tumor necrosis factor-α by equine monocytes

Medicine & Life Sciences

• Adenosine A2 Receptor Agonists 100%
• ATL 313 59%
• Horses 59%
• Lipopolysaccharides 53%
• Monocytes 51%
• Tumor Necrosis Factor-alpha 44%
• Adenosine A2A Receptors 31%
• ZM 241385 28%
• Adenosine 27%
• N-(4-acetylphenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy)acetamide 23%
• N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine 19%
• Adenosine A2 Receptor Antagonists 17%
• Purinergic P1 Receptor Agonists 16%
• Purinergic P1 Receptors 14%
• Adenosine A3 Receptor Agonists 9%
• Adenosine-5'-(N-ethylcarboxamide) 8%
• 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine 8%
• Anti-Inflammatory Agents 8%
• Purinergic P1 Receptor Antagonists 8%
• Adenosine A1 Receptors 7%
• Cytokines 7%
• Colforsin 6%
• Nucleosides 5%
• Physiological Phenomena 5%
• Adenylyl Cyclases 5%
• Reactive Oxygen Species 4%
• Neutrophils 4%
• Signal Transduction 4%
• Pharmaceutical Preparations 2%

Agriculture & Biology

• tumor necrosis factors 83%
• monocytes 65%
• adenosine 64%
• lipopolysaccharides 59%
• agonists 57%
• horses 51%
• receptors 42%
• antagonists 17%
• production economics 11%
• cytokines 6%
• anti-inflammatory agents 4%
• forskolin 4%
• blood 4%
• nucleosides 3%
• adenylate cyclase 3%
• anti-inflammatory activity 3%
• neutrophils 3%
• signal transduction 3%
• reactive oxygen species 2%
• tissues 1%